Details of the Drug

General Information of Drug (ID: DMF3AN7)

Drug Name

Loratadine

Synonyms

Aerotina; Alarin; Alavert; Alerpriv; Allertidin; Anhissen; Biloina; Bonalerg; Civeran; Claratyne; Clarinase; Claritin; Claritine; Clarityn; Clarityne; Clarium; Fristamin; Histaloran; Lergy; Lertamine; Lesidas; Lisino; Loracert; Loradex; Loradif; Loranox; Lorantis; Lorastine; Loratadina; Loratadinum; Loratidine; Loratyne; Loraver; Lorfast; Loritine; Lowadina; Nularef; Optimin; Polaratyne; Pylor; Restamine; Rhinase; Rinomex; Roletra; Sanelor; Sensibit; Sohotin; Tadine; Velodan; Versal; Zeos; Bedix Loratadina; Claratyne Cold; Claratyne Decongestant; Clarinase Reperabs; Claritin D; Claritin Hives Relief; Claritin Hives Relief Reditab; Claritin Reditabs; Claritin reditab; Clarityne Dy Repetabs; Loratadina [Spanish]; Loratadine Redidose; Loratadine Wyeth Brand; Loratadinum [Latin]; Sinhistan Dy; Talorat Dy; Wyeth Brand of Loratadine; L 9664; Sch 29851; Sch29851; Alavert (TN); AllergyX (TN); Children's Claritin; Claritin (TN); Claritine (TN); Clarityn (TN); Clarityne (TN); Clarityne-D; Flonidan (TN); Fristamin (TN); Lomilan (TN); Lorfast (TN); Rinolan (TN); Roletra (TN); Sch-29851; Symphoral (TN); Tidilor (TN); Alavert, Claritin, Loratadine; Loratadine [USAN:BAN:INN]; Loratadine (JAN/USAN/INN); Ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate; Ethyl 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylate; 1-Piperidenecarboxylic acid, 4-(8-chloro-5,6-duhydro-11H-benzo [5,6]cyclohepta[1,2-b]-pyridin-11-ylidene)-, ethyl ester; 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-, ethyl ester; 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester; 1-piperidinecarboxylic acid,4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-,ethyl ester; 4-(8-Chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylic Acid Ethyl Ester; 4-(8-Chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acidethyl ester; 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cycloheptal[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acid ethyl ester

Indication

Disease Entry	ICD 11	Status	REF
Allergy	4A80-4A85	Approved	[1]
Common cold	CA00	Approved	[2]
Seasonal allergic rhinitis	CA08.01	Approved	[2]
Vasomotor/allergic rhinitis	CA08	Approved	[2]
Allergic rhinitis	CA08.0	Discontinued in Phase 2	[3]
------------------------------------------------------------------------------------

Therapeutic Class

Antihistamines

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

382.9

Logarithm of the Partition Coefficient (xlogp)

5.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 6.14 mcgh/L [4]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 2.56 mcg/L [4]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1.14 h [4]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [5]
Clearance: The clearance of drug is 12 L/h/kg [6]
Elimination: 40% of loratadine is excreted in the urine, and 42% is eliminated in the faeces [7]
Half-life: The concentration or amount of drug in body reduced by one-half in 10 hours [4]
Metabolism: The drug is metabolized via the liver [8]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.43615 micromolar/kg/day [9]
Vd: The volume of distribution (Vd) of drug is 120 L/kg [10]
Water Solubility: The ability of drug to dissolve in water is measured as 0.005 mg/mL [5]

Chemical Identifiers

Formula: C22H23ClN2O2
IUPAC Name: ethyl 4-(13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene)piperidine-1-carboxylate
Canonical SMILES: CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1
InChI: InChI=1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3
InChIKey: JCCNYMKQOSZNPW-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3957
ChEBI ID: CHEBI:6538
CAS Number: 79794-75-5
DrugBank ID: DB00455
TTD ID: D06ABF
VARIDT ID: DR00541
INTEDE ID: DR0977
ACDINA ID: D00374

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histamine H1 receptor (H1R)	TTTIBOJ	HRH1_HUMAN	Antagonist	[11]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[12]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[13]
Cytochrome P450 2D6 (CYP2D6)_{Main DME}	DECB0K3	CP2D6_HUMAN	Substrate	[14]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[15]
Mephenytoin 4-hydroxylase (CYP2C19)_{Main DME}	DEGTFWK	CP2CJ_HUMAN	Substrate	[16]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[17]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[17]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Substrate	[17]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[18]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Alpha-1-antichymotrypsin (SERPINA3)	OT9BP2S0	AACT_HUMAN	Gene/Protein Processing	[19]
Angiotensin-converting enzyme 2 (ACE2)	OTTRZGU7	ACE2_HUMAN	Protein Interaction/Cellular Processes	[20]
Antileukoproteinase (SLPI)	OTUNFUU8	SLPI_HUMAN	Gene/Protein Processing	[21]
AP-1 complex subunit sigma-1A (AP1S1)	OTQ2H8DN	AP1S1_HUMAN	Gene/Protein Processing	[22]
Asparagine synthetase (ASNS)	OT8R922G	ASNS_HUMAN	Gene/Protein Processing	[19]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Gene/Protein Processing	[23]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Gene/Protein Processing	[24]
Caspase-7 (CASP7)	OTAPJ040	CASP7_HUMAN	Gene/Protein Processing	[25]
Caspase-8 (CASP8)	OTA8TVI8	CASP8_HUMAN	Protein Interaction/Cellular Processes	[24]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Protein Interaction/Cellular Processes	[24]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Allergy

ICD Disease Classification

4A80-4A85

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Histamine H1 receptor (H1R)	DTT	HRH1	6.74E-01	0.13	0.43
P-glycoprotein 1 (ABCB1)	DTP	P-GP	6.54E-01	1.95E-01	4.04E-01
Cytochrome P450 2C8 (CYP2C8)	DME	CYP2C8	5.57E-01	-7.89E-02	-7.93E-01
Cytochrome P450 2B6 (CYP2B6)	DME	CYP2B6	4.32E-01	4.39E-02	4.30E-01
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	8.46E-01	-6.63E-03	-4.49E-02
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	9.57E-01	9.43E-03	1.29E-01
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	9.62E-01	2.57E-02	1.10E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	8.70E-01	2.98E-02	1.22E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	2.35E-01	2.78E-02	2.09E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.76E-01	1.26E-01	8.27E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Loratadine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Arn-509	DMT81LZ	Moderate	Increased metabolism of Loratadine caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[26]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Loratadine caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[27]
Voriconazole	DMAOL2S	Moderate	Decreased metabolism of Loratadine caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[28]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Loratadine caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[29]
Clarithromycin	DM4M1SG	Minor	Decreased metabolism of Loratadine caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[30]
Troleandomycin	DMUZNIG	Minor	Decreased metabolism of Loratadine caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[30]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Loratadine caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[31]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Loratadine caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[28]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Loratadine caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[32]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Loratadine caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[33]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Loratadine caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[34]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Loratadine caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[35]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Loratadine caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[26]
Itraconazole	DMCR1MV	Minor	Decreased metabolism of Loratadine caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[36]
Terbinafine	DMI6HUW	Moderate	Decreased metabolism of Loratadine caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[37]
Miconazole	DMPMYE8	Minor	Decreased metabolism of Loratadine caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[36]
Ketoconazole	DMPZI3Q	Minor	Decreased metabolism of Loratadine caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[36]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Loratadine caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[38]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Loratadine caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[39]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Loratadine caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[40]
Efavirenz	DMC0GSJ	Moderate	Increased metabolism of Loratadine caused by Efavirenz mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[41]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Loratadine caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[42]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Loratadine caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[43]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Loratadine caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[44]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Loratadine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[26]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Loratadine caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[45]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Loratadine caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[46]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Loratadine caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[26]
Lumefantrine	DM29GAD	Moderate	Decreased metabolism of Loratadine caused by Lumefantrine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[28]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Loratadine caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[47]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Loratadine caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[48]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Loratadine caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[49]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Loratadine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[26]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Loratadine caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[50]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Loratadine caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[51]
Modafinil	DMYILBE	Minor	Increased metabolism of Loratadine caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[52]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Loratadine caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[53]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Loratadine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[54]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Loratadine caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[55]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Loratadine caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[56]
Bosentan	DMIOGBU	Moderate	Increased metabolism of Loratadine caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[57]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Loratadine and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[58]
Celecoxib	DM6LOQU	Moderate	Decreased metabolism of Loratadine caused by Celecoxib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[59]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Loratadine caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[26]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Loratadine caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[28]
Armodafinil	DMGB035	Minor	Increased metabolism of Loratadine caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[52]
LEE011	DMMX75K	Moderate	Decreased metabolism of Loratadine caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[60]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Loratadine caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[26]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Loratadine and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[58]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Loratadine and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[58]
Amiodarone	DMUTEX3	Moderate	Increased plasma concentrations of Loratadine and Amiodarone due to competitive inhibition of the same metabolic pathway.	Ventricular tachyarrhythmia [BC71]	[61]
-----------


⏷ Show the Full List of 51 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Aspartame	E00402	134601	Flavoring agent
Caprylic acid	E00017	379	Emulsifying agent; Flavoring agent; Surfactant
D&C red no. 27	E00381	83511	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearate	E00453	2724691	Emulsifying agent; Gelling agent; Glidant; Modified-release agent; Stiffening agent; lubricant
Sodium stearyl fumarate	E00545	23665634	lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Ascorbic acid	E00579	54670067	Acidulant; Antioxidant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Butylhydroxyanisole	E00308	24667	Antimicrobial preservative; Antioxidant
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Dextrin	E00359	62698	Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Eisenoxyd	E00585	56841934	Colorant
Glycerin	E00026	753	Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Hexahydric alcohol	E00083	5780	Diluent; Flavoring agent; Humectant; Plasticizing agent
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium bicarbonate	E00424	516892	Alkalizing agent; Diluent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 29 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Loratadine 10 mg tablet	10 mg	Disintegrating Tablet	Oral
Loratadine 5 mg tablet	5 mg	Chewable Tablet	Oral
Loratadine 10 mg tablet	10 mg	24 HR Oral Tablet	Oral
Loratadine 10 mg capsule	10 mg	Oral Capsule	Oral
Loratadine 10 mg tablet	10 mg	Disintegrating Oral Tablet	Oral
Loratadine 5 mg tablet	5 mg	Disintegrating Oral Tablet	Oral
Loratadine 10 mg tablet	10 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7216).
2	Loratadine FDA Label
3	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015252)
4	Loratadine: a nonsedating antihistamine with once-daily dosing. DICP. 1989 Jun;23(6):445-50.
5	BDDCS applied to over 900 drugs
6	Clissold SP, Sorkin EM, Goa KL: Loratadine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs. 1989 Jan;37(1):42-57.
7	Health Canada Product Monograph: Claritin (loratadine)
8	Mezincescu A, Karthikeyan VJ, Nadar SK: Ranolazine: A true pluripotent cardiovascular drug or jack of all trades, master of none? Sultan Qaboos Univ Med J. 2018 Feb;18(1):e13-e23. doi: 10.18295/squmj.2018.18.01.003. Epub 2018 Apr 4.
9	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
10	Comparative Pharmacology of the H1 Antihistamines
11	Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jan;23(2):63-6.
12	P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos. 2003 Mar;31(3):312-8.
13	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
14	In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. Drug Metab Dispos. 2001 Sep;29(9):1173-5.
15	In vitro inhibition of human liver drug metabolizing enzymes by second generation antihistamines. Chem Biol Interact. 1999 Nov 15;123(1):63-79.
16	Advances in high-resolution MS and hepatocyte models solve a long-standing metabolism challenge: the loratadine story. Bioanalysis. 2016 Aug;8(16):1645-62.
17	Metabolism of loratadine and further characterization of its in vitro metabolites. Drug Metab Lett. 2009 Aug;3(3):162-70.
18	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
19	A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
20	Testing of the inhibitory effects of loratadine and desloratadine on SARS-CoV-2 spike pseudotyped virus viropexis. Chem Biol Interact. 2021 Apr 1;338:109420. doi: 10.1016/j.cbi.2021.109420. Epub 2021 Feb 18.
21	An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
22	In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies. Toxicol Sci. 2007 Sep;99(1):162-73.
23	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
24	H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells. Exp Hematol. 2010 Oct;38(10):896-907. doi: 10.1016/j.exphem.2010.05.008. Epub 2010 Jun 1.
25	Palmitate increases the susceptibility of cells to drug-induced toxicity: an in vitro method to identify drugs with potential contraindications in patients with metabolic disease. Toxicol Sci. 2012 Oct;129(2):346-62. doi: 10.1093/toxsci/kfs208. Epub 2012 Jun 14.
26	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
27	Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
28	Cerner Multum, Inc. "Australian Product Information.".
29	Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
30	Ament PW, Paterson A "Drug interactions with the nonsedating antihistamines." Am Fam Physician 56 (1997): 223. [PMID: 9225677]
31	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
32	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
33	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
34	Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
35	Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
36	Product Information. Claritin (loratadine). Schering Laboratories, Kenilworth, NJ.
37	AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
38	Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
39	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
40	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
41	Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
42	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
43	Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
44	Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
45	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
46	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
47	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
48	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
49	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
50	Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
51	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
52	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
53	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
54	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
55	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
56	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
57	Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
58	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
59	Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
60	DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
61	Atar S, Freedberg NA, Antonelli D, Rosenfeld T "Torsades de pointes and QT prolongation due to a combination of loratadine and amiodarone." Pacing Clin Electrophysiol 26 (2003): 785-6. [PMID: 12698686]